CClinicalTrials.gg
CompletedNCT03047967Updated Feb 20, 2025

Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns

An interventional study of lung function tests and Nasal brushing in Pregnancy Related, Tobacco Smoking and Lung Smokers, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 2 Days to 6 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
2 Days to 6 Days
Sex
All
01

Study summary

Despite public campaigns to prevent cigarette smoking, it's about 20% of women who keep on smoking during pregnancy, exposing their fetus to prenatal tobacco adverse effects. Although environnemental tobacco smoke exposure effects are well known, consequences of prenatal tobacco smoke exposure (PTSE) need better caracterization. Previous animal study from our group have shown, in prenatal nicotine exposed mouse pups, alterations in tracheal epithelial structure similar to those observed in KO α7-nAChR mouse pups. These findings support the hypothesis that α7-nAChR are involved in the process of deleterious effects of tobacco smoking on respiratory epithelium development. The purpose of the present clinical study is to compare PTSE neonates with controls according to lung function and respiratory epithelial functionality. At the age of 3 days, small respiratory epithelium fragments will be obtained from gentle nasal brushing performed under antalgic premedication according to the method we previously published. Epithelium samples will be used for in vitro studies of α7-nAChR and CFTR functionality. Between the ages of 2 and 6 weeks, lung function testing will be performed, by means of baby-body plethysmography.

02

Conditions studied

  • Pregnancy Related
  • Tobacco Smoking
  • Lung Smokers
  • Newborn
03

In context

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Days to 6 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • inborn full-term neonate
  • social security affiliation
  • informed consent form signed by parents

Exclusion criteria

Exclusion Criteria:

  • prematurity \< 35GW
  • gemellary pregnancy
  • Birth weight \< 2200 g
  • neonatal respiratory distress syndrome (nasal oxygenotherapy > 24 hours, invasive or noninvasive ventilation)
  • neonatal malformation with conséquences on lung function
  • neonatal liver or renal failure
  • high risk of heritable lung disease
  • contra-indication to saccharose or paracetamol antalgic use
  • language barrier,
  • mother refusal to declare or precise her tobacco consumption
  • no social security cover
  • informed consent form not signed
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    PTSE

    Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing

    Diagnostic Test: lung function tests · Diagnostic Test: Nasal brushing

  • Experimental
    control

    Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing

    Diagnostic Test: lung function tests · Diagnostic Test: Nasal brushing

Interventions

  • Diagnostic testlung function tests

    baby-body plethysmography

  • Diagnostic testNasal brushing

    Epithelial sample collecting for in vitro study

06

What researchers measure

Primary outcomes

  1. α7-nAChR functionnality

    calcium influx mesurements on epithelial fragments by monitoring changes in Fluo-4 fluorescence intensity. Fluo-4 is a fluorescent dye which fluorescence is modified by its linkage to Calcium. Its fluorescence changes measurements shows calcium cellular flows.

    Time frame: day 3

  2. CFTR functionality

    chlorid influx study on epithelial fragmentsby monitoring changes in spq fluorescence intensity. sqp is a fluorescent dye which fluorescence is modified by its linkage to Chlore. Its fluorescence changes measurements shows chlore cellular flows.

    Time frame: day 3

Secondary outcomes

  1. Lung function test

    baby-body plethysmography that study ventilation in asleep infants (measurement of tidal volumes, respiratory frequency, airway resistances, respiratory system compliance, maximal expiratory flows)

    Time frame: between ages 2 and 6 week

  2. ciliary frequency mesurement

    On epithelial fragments. By using vidéo microscopy and select several delimited zone where ciliary frequency is measured. Then a mean freqeuncy is calculated

    Time frame: day 3

07

Study locations

1 site
  • Inserm
    Paris, 75000, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03047967
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Nov 10, 2017
Primary completion
Feb 9, 2018
Completion
Feb 9, 2019
Last update
Feb 20, 2025

Study contacts

Pierre MAURAN, MD PHD
study director · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion